Amedisys Stock Operating Margin
| AMED Stock | USD 90.40 0.38 0.42% |
Amedisys fundamentals help investors to digest information that contributes to Amedisys' financial success or failures. It also enables traders to predict the movement of Amedisys Stock. The fundamental analysis module provides a way to measure Amedisys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amedisys stock.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | 0.09 | 0.09 |
Amedisys | Operating Margin |
Amedisys Company Operating Margin Analysis
Amedisys' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Amedisys Operating Margin | 0.08 % |
Most of Amedisys' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amedisys is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Amedisys Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Amedisys is extremely important. It helps to project a fair market value of Amedisys Stock properly, considering its historical fundamentals such as Operating Margin. Since Amedisys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amedisys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amedisys' interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Amedisys Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Amedisys has an Operating Margin of 0.0798%. This is 100.23% lower than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 101.45% lower than that of the firm.
Amedisys Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amedisys' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amedisys could also be used in its relative valuation, which is a method of valuing Amedisys by comparing valuation metrics of similar companies.Amedisys is currently under evaluation in operating margin category among related companies.
Amedisys Fundamentals
| Return On Equity | -0.0098 | ||||
| Return On Asset | 0.0598 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 3.38 B | ||||
| Shares Outstanding | 32.67 M | ||||
| Shares Owned By Insiders | 2.26 % | ||||
| Shares Owned By Institutions | 96.17 % | ||||
| Number Of Shares Shorted | 2.49 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 2.81 X | ||||
| Price To Sales | 1.34 X | ||||
| Revenue | 2.24 B | ||||
| Gross Profit | 453.98 M | ||||
| EBITDA | 216.91 M | ||||
| Net Income | (9.75 M) | ||||
| Cash And Equivalents | 17.96 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 487.21 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 32.65 X | ||||
| Cash Flow From Operations | 137.19 M | ||||
| Short Ratio | 7.11 X | ||||
| Earnings Per Share | (0.30) X | ||||
| Price To Earnings To Growth | 1.35 X | ||||
| Target Price | 97.78 | ||||
| Number Of Employees | 19 K | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 2.97 B | ||||
| Total Asset | 2.06 B | ||||
| Retained Earnings | 747.92 M | ||||
| Working Capital | 23.21 M | ||||
| Current Asset | 175.26 M | ||||
| Current Liabilities | 175.19 M | ||||
| Net Asset | 2.06 B |
About Amedisys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amedisys's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amedisys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amedisys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Amedisys
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.Moving together with Amedisys Stock
| 0.91 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
Moving against Amedisys Stock
| 0.77 | HIMS | Hims Hers Health Financial Report 13th of May 2024 | PairCorr |
| 0.66 | ELMD | Electromed | PairCorr |
| 0.54 | HOLX | Hologic Financial Report 6th of May 2024 | PairCorr |
| 0.53 | BAX | Baxter International Financial Report 25th of April 2024 | PairCorr |
| 0.51 | ALC | Alcon AG Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.
The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Amedisys Piotroski F Score and Amedisys Altman Z Score analysis. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.40) | Earnings Share (0.30) | Revenue Per Share 68.603 | Quarterly Revenue Growth 0.016 | Return On Assets 0.0598 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.